Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
HOME > REGULATORY
REGULATORY
- JPMA Official Calls for Partial Introduction of CDISC-Based Electronic Applications; Runup Period too Short
June 30, 2014
- Benefits of Electronic Applications to Be Shared by Patients, Companies, and Regulatory Authorities: MHLW Exec
June 30, 2014
- PAFSC’s Second Committee Supports Approval of IFN-Free Hepatitis C Treatments
June 30, 2014
- Chuikyo to Resume Discussions on Diovan Ads’ Impact on Healthcare Finances
June 27, 2014
- MHLW to Conduct Hearings over CASE-J Study, Take “Appropriate Action” against Takeda: Minister
June 27, 2014
- Drugs under Simultaneous Global Development May also Be Eligible for New Fast-Track Review System: MHLW Exec
June 26, 2014
- Govt Approves Economic Strategies, Chuikyo Likely to Discuss NHI Price Revision Frequency
June 25, 2014
- Ryukaikon to Meet on July 2; FY2013 Price Settlement Rates to Be Reported
June 25, 2014
- MHLW Issues Notification on Electronic Applications
June 24, 2014
- Blopress Excluded from Generic Share Calculation until September
June 23, 2014
- Broad Perspective Important for Vaccination Policy: CDC Official
June 23, 2014
- LDP OKs Revised Version of Draft Economic, Fiscal Policy Guidelines
June 20, 2014
- First Generics of Diovan, Blopress AGs Join Reimbursement List
June 20, 2014
- PAFSC’s Second Committee to Discuss Approval for IFN-Free Hepatitis C Treatments on June 26
June 19, 2014
- Drug Price Settlement Rate for March 2014 at 98.4%: MHLW
June 19, 2014
- LDP Members Request Govt to Stay with Current Biennial NHI Price Revision
June 18, 2014
- MHLW on Tap to Launch Expedited Drug Review System in 2015
June 18, 2014
- Govt Weighs Applying Mixed Care Scheme to Low Cost-Effective Drugs: Draft Growth Strategy
June 17, 2014
- PMDA Reviewing Osteoporosis Treatment Forteo for Risk of Shock, Anaphylaxis
June 17, 2014
- “Annual” NHI Price Revision Erased from Gov’t Draft Policy Blueprint
June 16, 2014
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…